Where is SRPT stock listed?

Sarepta Therapeutics, Inc. trades under the ticker SRPT on NASDAQ.

How can I research SRPT's financials and filings?

Vantafin provides Sarepta Therapeutics, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the SRPT profile.

Sarepta Therapeutics, Inc. (SRPT) stock profile

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection for the treatment of Duchenne muscular dystrophy in patients with confirmed mutation of the dystrophin gene amenable to exon 51 skipping, and VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation amenable to exon 53 skipping. Sarepta is also developing AMONDYS 45, a product candidate using phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Sarepta was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Key facts

Symbol	SRPT
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology
CEO	Douglas S. Ingram
Employees	1372
Headquarters	Cambridge, MA, US
IPO	1997-06-04
Website	www.sarepta.com

Explore SRPT on Vantafin

Frequently asked questions

What does Sarepta Therapeutics, Inc. (SRPT) do?: Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection for the treatment of Duchenne muscular dystrophy in patients with confirmed mutation of the dystrophin gene amenable to exon 51 skipping, and VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation amenable to exon 53 skipping. Sarepta is also developing AMONDYS 45, a product candidate using phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Sarepta was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Where is SRPT stock listed?: Sarepta Therapeutics, Inc. trades under the ticker SRPT on NASDAQ.
How can I research SRPT's financials and filings?: Vantafin provides Sarepta Therapeutics, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the SRPT profile.

Sarepta Therapeutics, Inc. (SRPT) stock profile

Key facts

Symbol	SRPT
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology
CEO	Douglas S. Ingram
Employees	1372
Headquarters	Cambridge, MA, US
IPO	1997-06-04
Website	www.sarepta.com

Explore SRPT on Vantafin

Frequently asked questions

What does Sarepta Therapeutics, Inc. (SRPT) do?: Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection for the treatment of Duchenne muscular dystrophy in patients with confirmed mutation of the dystrophin gene amenable to exon 51 skipping, and VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation amenable to exon 53 skipping. Sarepta is also developing AMONDYS 45, a product candidate using phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Sarepta was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Where is SRPT stock listed?: Sarepta Therapeutics, Inc. trades under the ticker SRPT on NASDAQ.
How can I research SRPT's financials and filings?: Vantafin provides Sarepta Therapeutics, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the SRPT profile.